Takeda

Why trials sponsored by Takeda stopped, in this sample of ClinicalTrials.gov.

22 stopped trials with a clear reason; 59% ended for non-scientific reasons.

Where it ranks

• #1 of 90 sponsors by share of trials stopped for: safety (27%).

Among ranked sponsors in this sample. Shares of stopped trials, not failure rates. See all scorecards.

Trials

• A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine
  NCT06422377 · TERMINATED · funding business
  “Business decision unrelated to patient safety.”
• A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)
  NCT05863819 · WITHDRAWN · funding business
  “Business reason, unrelated to product safety”
• A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)
  NCT05494593 · WITHDRAWN · slow accrual
  “Study was closed due to enrollment challenges”
• A Study of TAK-994 in Adults With Narcolepsy
  NCT04820842 · TERMINATED · safety
  “A safety signal has emerged in Phase 2 studies of TAK-994. As an immediate precautionary measure, Takeda has suspended dosing of patients and has decided to stop Phase 2 studies early.”
• A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
  NCT04776018 · TERMINATED · funding business
  “Business Reasons”
• Bioavailability and Food Effect Study of Two Formulations of TAK-906
  NCT04831502 · WITHDRAWN · funding business
  “Business decision”
• A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
  NCT04501614 · TERMINATED · safety
  “Phase 1 enrollment was terminated due to dose-limiting toxicities, thus the study was terminated by Sponsor.”
• A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) Brain Enzyme Occupancy of TAK-418 After Single-Dose Oral Administration in Healthy Participants
  NCT04202497 · TERMINATED · logistics pi
  “Study was prematurely terminated because of administrative reasons.”
• A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma
  NCT04074330 · TERMINATED · slow accrual
  “Enrolment Challenges”
• A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
  NCT03173092 · TERMINATED · other
  “All participants on the study have concluded treatment, core study activities are complete, and the scientific goals of the study have been met.”
• Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study
  NCT02760615 · WITHDRAWN · slow accrual
  “No enrollment”
• Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants
  NCT02769065 · TERMINATED · funding business
  “Terminated prematurely as data from cohort no longer needed due to indication change.”
• An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections
  NCT02302092 · TERMINATED · funding business
  “Study was prematurely terminated due to administrative and strategic reasons”
• Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone
  NCT02381288 · TERMINATED · futility
  “Sponsor decision to terminate the study because the study did not meet the primary endpoint.”
• Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
  NCT02393378 · TERMINATED · funding business
  “Strategic decision - to understand data from psoriasis study - NCT02129777 and wait for results of formal proof of concept study - NCT02379091.”
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants
  NCT02209506 · TERMINATED · safety
  “Long-term animal toxicology findings (see detailed description).”
• Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)
  NCT02176486 · TERMINATED · slow accrual
  “Insufficient enrollment, no safety or efficacy concerns”
• Fasiglifam 25 mg BID vs 50 mg QD
  NCT01982253 · TERMINATED · safety
  “Due to potential concerns about liver safety (See Detailed Description)”
• MLN3126 Single Rising Dose Study
  NCT02447458 · TERMINATED · regulatory
  “Site non-compliance to GCP (No safety concerns. See detailed description)”
• Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
  NCT01931566 · TERMINATED · futility
  “Lack of efficacy of the drug; no safety concern”
• Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes
  NCT01647542 · TERMINATED · safety
  “Due to potential concerns about liver safety (See Detailed Description)”
• Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
  NCT00762112 · TERMINATED · safety
  “Hepatic safety signal identified.”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.